Sign Me Up!
New Alzheimer's Medication: Kisunla - What You Need to Know (Virtual)
Summary
The U.S. Food and Drug Administration has approved Kisunla (donanemab-azbt) injection for the treatment of Alzheimer’s disease. Treatment with Kisunla should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was studied in the clinical trials. Dr Pauldurai will talk about the new drug, benefits, and answer questions you may have about it.
Zoom link provided upon registration.
Tuesday, August 27 at 7:00 pm
Event Registration is closed.
Zoom link provided upon registration.
Tuesday, August 27 at 7:00 pm